Phase4 Ventures Spins Out of Nomura, Focuses on Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Management buys out venture capital business Phase4 Ventures from Nomura, and plans increased investment in Europe.
You may also be interested in...
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”